Literature DB >> 19214194

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Andrew J Pollard1, Kirsten P Perrett, Peter C Beverley.   

Abstract

Polysaccharide-encapsulated organisms are the leading cause of bacterial meningitis and pneumonia in children. The use of protein-polysaccharide conjugate vaccines in developed countries over the past two decades has markedly decreased the burden of disease and mortality from these organisms through direct protection of the immunized and through herd immunity. In the next decade, the widespread use of conjugate vaccines in the developing world should prevent millions of deaths. In this Science and Society article, we describe how vaccine-induced immunity wanes rapidly after vaccination in early childhood and argue that strategies that sustain protection in the population must be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214194     DOI: 10.1038/nri2494

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  65 in total

Review 1.  Antigen dependent and independent mechanisms that sustain serum antibody levels.

Authors:  Elisabetta Traggiai; Roberto Puzone; Antonio Lanzavecchia
Journal:  Vaccine       Date:  2003-06-01       Impact factor: 3.641

2.  The use of combination vaccines has improved timeliness of vaccination in children.

Authors:  Helen Kalies; Veit Grote; Thomas Verstraeten; Luc Hessel; Heinz-Josef Schmitt; Rüdiger von Kries
Journal:  Pediatr Infect Dis J       Date:  2006-06       Impact factor: 2.129

Review 3.  The preventable burden of pneumococcal disease in the developing world.

Authors:  J A G Scott
Journal:  Vaccine       Date:  2006-09-18       Impact factor: 3.641

4.  Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults.

Authors:  R Borrow; H Joseph; N Andrews; M Acuna; E Longworth; S Martin; N Peake; R Rahim; P Richmond; E Kaczmarski; E Miller
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

5.  Meningococcal disease: public health burden and control.

Authors:  E Tikhomirov; M Santamaria; K Esteves
Journal:  World Health Stat Q       Date:  1997

6.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Authors:  Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

7.  Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.

Authors:  Ray Borrow; David Goldblatt; Adam Finn; Joanna Southern; Lindsey Ashton; Nick Andrews; Gouri Lal; Christine Riley; Rukhsana Rahim; Keith Cartwright; Geraldine Allan; Elizabeth Miller
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

8.  Host and environmental factors associated with Hib in England, 1998-2002.

Authors:  J McVernon; N Andrews; M Slack; R Moxon; M Ramsay
Journal:  Arch Dis Child       Date:  2007-09-05       Impact factor: 3.791

9.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

10.  Social behavior and meningococcal carriage in British teenagers.

Authors:  Jenny MacLennan; George Kafatos; Keith Neal; Nick Andrews; J Claire Cameron; Richard Roberts; Meirion R Evans; Kathy Cann; David N Baxter; Martin C J Maiden; James M Stuart
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

View more
  132 in total

1.  Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.

Authors:  Julia Hutter; Marcela F Pasetti; Doh Sanogo; Milagritos D Tapia; Samba O Sow; Myron M Levine
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

Review 2.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

3.  Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.

Authors:  Morven S Edwards; Heidi J Lane; Sharon L Hillier; Marcia A Rench; Carol J Baker
Journal:  Vaccine       Date:  2012-04-24       Impact factor: 3.641

4.  Synthesis of multivalent glycopeptide conjugates that mimic an HIV epitope.

Authors:  Jennifer K Bailey; Dung N Nguyen; Satoru Horiya; Isaac J Krauss
Journal:  Tetrahedron       Date:  2016-07-29       Impact factor: 2.457

Review 5.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

6.  Challenges in infant immunity: implications for responses to infection and vaccines.

Authors:  Mercy PrabhuDas; Becky Adkins; Hayley Gans; Christopher King; Ofer Levy; Octavio Ramilo; Claire-Anne Siegrist
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

7.  Impact of vaccination programs against measles, varicella and meningococcus C in Italy and in Tuscany and public health policies in the last decades.

Authors:  A Bechini; M Chellini; E Pellegrino; E Tiscione; C Lorini; G Bonaccorsi; P Bonanni; S Boccalini
Journal:  J Prev Med Hyg       Date:  2018-06-01

Review 8.  Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.

Authors:  Raphael Simon; Myron M Levine
Journal:  Hum Vaccin Immunother       Date:  2012-02-28       Impact factor: 3.452

9.  The effect of haptens on protein-carrier immunogenicity.

Authors:  Tal Gefen; Jacob Vaya; Soliman Khatib; Irena Rapoport; Meital Lupo; Eilon Barnea; Arie Admon; Elimelech Dan Heller; Elina Aizenshtein; Jacob Pitcovski
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 10.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.